Treatment of Irresectable Colorectal Liver Metastases by Combination of Liver Resection and Percutaneous Tumor Ablation: Mid-term Outcome.

IF 2 4区 医学 Q3 RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING
Tanja Lokancevic, Sebastian Keil, Philipp Bruners, Sven Lang, Iakovos Amygdalos, Christiane K Kuhl, Peter Isfort, Emona Staudacher
{"title":"Treatment of Irresectable Colorectal Liver Metastases by Combination of Liver Resection and Percutaneous Tumor Ablation: Mid-term Outcome.","authors":"Tanja Lokancevic, Sebastian Keil, Philipp Bruners, Sven Lang, Iakovos Amygdalos, Christiane K Kuhl, Peter Isfort, Emona Staudacher","doi":"10.1055/a-2781-8926","DOIUrl":null,"url":null,"abstract":"<p><strong>Purpose: </strong>Primary resection of liver metastases in colorectal cancer remains the leading curative approach. However, a small future liver remnant or central localization of metastases often prevent resectability. In such cases, combining resection with percutaneous ablation may offer a curative-intent treatment option. This study aims to evaluate the oncologic results and morbidity of this combined treatment.</p><p><strong>Materials and methods: </strong>In this retrospective study, 21 patients with advanced colorectal liver metastases underwent a two-stage treatment consisting of planned incomplete resection and percutaneous ablation. Outcomes assessed included overall survival and intrahepatic progression-free survival. Main exclusion criteria were extrahepatic disease and ablation of metastases > 3 cm. Results are reported as medians with 95% confidence intervals and standard deviation.</p><p><strong>Results: </strong>The median number of preoperative intrahepatic metastases was 5 [2-13]. Follow-up was available for 95% of patients, with a median follow-up of 21 months. Intra- und extrahepatic recurrences occurred in 81% (17/21). Median intrahepatic progression-free survival was 5 [0-44] months. Median overall survival was 36.5 [6.6-55] months, resulting in a 1-year survival rate of 91%. Twelve patients (57%) passed away. Technical success was achieved in 90%. Three major complications occurred, all of which were successfully treated.</p><p><strong>Conclusion: </strong>In patients with partially unresectable colorectal liver metastases, a two-stage approach combining resection and percutaneous ablation represents a potential curative-intent strategy, particularly when intraoperative ablation is not feasible. Despite high recurrence rates, OS was comparatively long relative to systemic therapy. Further studies are needed to explore treatment sequencing, perioperative therapies, and advanced ablation technologies for optimizing the concept. Ultimately, treatment must be individualized based on the patient's disease profile and institutional capabilities.</p><p><strong>Key points: </strong>· A two-stage approach combining resection and percutaneous ablation represents a potential curative-intent strategy in partially irresectable colorectal liver metastases.. · High recurrence rates occur, but overall survival remains comparatively long.. · Individualized, interdisciplinary treatment planning optimizes patient outcomes.. · Further research is needed on sequencing, perioperative strategies, and ablation technologies..</p><p><strong>Citation format: </strong>· Lokancevic T, Keil S, Bruners P et al. Treatment of Irresectable Colorectal Liver Metastases by Combination of Liver Resection and Percutaneous Tumor Ablation: Mid-term Outcome. Rofo 2026; DOI 10.1055/a-2781-8926.</p>","PeriodicalId":21490,"journal":{"name":"Rofo-fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren","volume":" ","pages":"1310-1317"},"PeriodicalIF":2.0000,"publicationDate":"2026-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Rofo-fortschritte Auf Dem Gebiet Der Rontgenstrahlen Und Der Bildgebenden Verfahren","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1055/a-2781-8926","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/2/6 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"RADIOLOGY, NUCLEAR MEDICINE & MEDICAL IMAGING","Score":null,"Total":0}
引用次数: 0

Abstract

Purpose: Primary resection of liver metastases in colorectal cancer remains the leading curative approach. However, a small future liver remnant or central localization of metastases often prevent resectability. In such cases, combining resection with percutaneous ablation may offer a curative-intent treatment option. This study aims to evaluate the oncologic results and morbidity of this combined treatment.

Materials and methods: In this retrospective study, 21 patients with advanced colorectal liver metastases underwent a two-stage treatment consisting of planned incomplete resection and percutaneous ablation. Outcomes assessed included overall survival and intrahepatic progression-free survival. Main exclusion criteria were extrahepatic disease and ablation of metastases > 3 cm. Results are reported as medians with 95% confidence intervals and standard deviation.

Results: The median number of preoperative intrahepatic metastases was 5 [2-13]. Follow-up was available for 95% of patients, with a median follow-up of 21 months. Intra- und extrahepatic recurrences occurred in 81% (17/21). Median intrahepatic progression-free survival was 5 [0-44] months. Median overall survival was 36.5 [6.6-55] months, resulting in a 1-year survival rate of 91%. Twelve patients (57%) passed away. Technical success was achieved in 90%. Three major complications occurred, all of which were successfully treated.

Conclusion: In patients with partially unresectable colorectal liver metastases, a two-stage approach combining resection and percutaneous ablation represents a potential curative-intent strategy, particularly when intraoperative ablation is not feasible. Despite high recurrence rates, OS was comparatively long relative to systemic therapy. Further studies are needed to explore treatment sequencing, perioperative therapies, and advanced ablation technologies for optimizing the concept. Ultimately, treatment must be individualized based on the patient's disease profile and institutional capabilities.

Key points: · A two-stage approach combining resection and percutaneous ablation represents a potential curative-intent strategy in partially irresectable colorectal liver metastases.. · High recurrence rates occur, but overall survival remains comparatively long.. · Individualized, interdisciplinary treatment planning optimizes patient outcomes.. · Further research is needed on sequencing, perioperative strategies, and ablation technologies..

Citation format: · Lokancevic T, Keil S, Bruners P et al. Treatment of Irresectable Colorectal Liver Metastases by Combination of Liver Resection and Percutaneous Tumor Ablation: Mid-term Outcome. Rofo 2026; DOI 10.1055/a-2781-8926.

肝切除联合经皮肿瘤消融治疗不可切除的结直肠癌肝转移:中期结果。
原发性肝转移切除术仍然是结直肠癌的主要治疗方法。然而,小的肝脏残余或转移灶的中心定位往往阻止可切除性。在这种情况下,联合切除与经皮消融可能提供一种治愈意图的治疗选择。本研究旨在评估这种联合治疗的肿瘤学结果和发病率。在这项回顾性研究中,21例晚期结直肠肝转移患者接受了两期治疗,包括计划的不完全切除和经皮消融。评估的结果包括总生存期和肝内无进展生存期。主要的排除标准是肝外病变和转移灶消融≤3cm。结果以95%置信区间和标准差的中位数报告。术前肝内转移的中位数为5例[2-13]。95%的患者可随访,中位随访时间为21个月。肝内和肝外复发占81%(17/21)。中位肝内无进展生存期为5[0-44]个月。中位总生存期为36.5[6.6-55]个月,1年生存率为91%。12例患者(57%)死亡。技术成功率达90%。发生了三种主要并发症,均得到成功治疗。对于部分不可切除的结直肠肝转移患者,两期手术联合切除和经皮消融是一种潜在的治疗策略,特别是当术中消融不可行的情况下。尽管复发率高,但相对于全身治疗,OS的持续时间相对较长。需要进一步的研究来探索治疗顺序、围手术期治疗和先进的消融技术来优化这一概念。最终,治疗必须根据患者的疾病概况和机构能力进行个体化。·联合切除和经皮消融的两阶段方法代表了部分不可切除的结直肠癌肝转移的潜在治愈意图策略。·复发率高,但总体生存期相对较长。·个性化、跨学科的治疗计划可优化患者的治疗效果。·需要进一步研究测序、围手术期策略和消融技术。·Lokancevic T, Keil S, Bruners P等。肝切除联合经皮肿瘤消融治疗不可切除的结直肠癌肝转移:中期结果。Rofo 2026;DOI 10.1055 / - 2781 - 8926。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.20
自引率
5.60%
发文量
340
期刊介绍: Die RöFo veröffentlicht Originalarbeiten, Übersichtsartikel und Fallberichte aus dem Bereich der Radiologie und den weiteren bildgebenden Verfahren in der Medizin. Es dürfen nur Arbeiten eingereicht werden, die noch nicht veröffentlicht sind und die auch nicht gleichzeitig einer anderen Zeitschrift zur Veröffentlichung angeboten wurden. Alle eingereichten Beiträge unterliegen einer sorgfältigen fachlichen Begutachtung. Gegründet 1896 – nur knapp 1 Jahr nach der Entdeckung der Röntgenstrahlen durch C.W. Röntgen – blickt die RöFo auf über 100 Jahre Erfahrung als wichtigstes Publikationsmedium in der deutschsprachigen Radiologie zurück. Sie ist damit die älteste radiologische Fachzeitschrift und schafft es erfolgreich, lange Kontinuität mit dem Anspruch an wissenschaftliches Publizieren auf internationalem Niveau zu verbinden. Durch ihren zentralen Platz im Verlagsprogramm stellte die RöFo die Basis für das heute umfassende und erfolgreiche Radiologie-Medienangebot im Georg Thieme Verlag. Besonders eng verbunden ist die RöFo mit der Geschichte der Röntgengesellschaften in Deutschland und Österreich. Sie ist offizielles Organ von DRG und ÖRG und die Mitglieder der Fachgesellschaften erhalten die Zeitschrift im Rahmen ihrer Mitgliedschaft. Mit ihrem wissenschaftlichen Kernteil und dem eigenen Mitteilungsteil der Fachgesellschaften bietet die RöFo Monat für Monat ein Forum für den Austausch von Inhalten und Botschaften der radiologischen Community im deutschsprachigen Raum.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书